Tag Archives: ENI

Hot Stocks To Invest In Right Now

Corecivic Inc (NYSE:CXW) saw strong trading volume on Friday . 12,807,807 shares traded hands during mid-day trading, an increase of 1,227% from the previous session’s volume of 965,253 shares.The stock last traded at $23.42 and had previously closed at $22.53.

Several analysts have commented on the stock. Zacks Investment Research upgraded shares of Corecivic from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Wednesday. ValuEngine cut shares of Corecivic from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Corecivic has an average rating of “Hold” and a consensus target price of $32.50.

Hot Stocks To Invest In Right Now: Nuveen Mortgage Opportunity Term Fund(JLS)

Nuveen Mortgage Opportunity Term Fund (the Fund) is a non-diversified closed-end registered investment company. The Funds’ investment adviser is Nuveen Fund Advisors, LLC. The Fund’s investment objective is to generate attractive total returns through opportunistic investments in mortgage backed security (MBS). The Fund seeks to achieve its investment objective by investing primarily in non-agency residential mortgage-backed securities (RMBS) and commercial mortgage-backed securities (CMBS). The Fund also invests up to 20% of its managed assets in other permitted investments, including cash and cash equivalents, the United States treasury securities, non-mortgage related asset-backed securities, inverse floating rate securities, municipal securities, interest rate futures, interest rate swaps and swaptions, non-MBS credit default swaps, and other synthetic mortgage-related exposure, including equity investments in mortgage real estate investment trusts. Advisors’ Opinion:

  • [By Joseph Griffin]

    Nuveen Mortgage Opportunity Term Fund (NYSE:JLS) declared a monthly dividend on Wednesday, August 1st, NASDAQ reports. Shareholders of record on Wednesday, August 15th will be given a dividend of 0.113 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a yield of 5.72%. The ex-dividend date is Tuesday, August 14th.

Hot Stocks To Invest In Right Now: CryoPort, Inc.(CYRX)

CryoPort, Inc. provides cryogenic logistics solutions to the life sciences industry in the United States, Europe, Asia, and internationally. The company offers Cryoportal, a cloud-based logistics management software that automates the entry of orders, prepares customs documentation, and facilitates status and location monitoring of shipped orders while in transit; and CryoPort Express Shippers, which are dry cryogenic shippers that use liquid nitrogen contained inside a vacuum insulated vessel, which serves as a refrigerant to provide stable storage temperatures. It also provides Cryoport Express Standard Shippers, which are re-usable dry vapor liquid nitrogen storage containers for holding the biological material in the inner chamber; CryoPort Express High Volume Shippers, which use a dry vapor liquid nitrogen technology to maintain temperatures; and Cryoport Express CXVC1 Shippers that provides solutions related to the shipment of time- and temperature-critical, as well as frozen and refrigerated transport of biological materials, such as stem cells, cell lines, pharmaceutical clinical trial samples, gene biotechnology, infectious materials handling, animal, and human reproduction. In addition, the company offers CryoPort Express Smart Pak, a self-contained automated data logger, which records cryogenic temperatures of samples shipped in CryoPort Express Shippers; CryoPort Express Analytics to track the time-based metrics for order processing time and on-time deliveries, as well as profiling shipping lanes to determine average transit times and predicting shipping exceptions based on historical metric; and biological material holders that are containment bags used in connection with the shipment of infectious or dangerous goods using the CryoPort Express Shippers. CryoPort, Inc. has a strategic alliance with Liventa Bioscience, Inc. The company was founded in 1999 and is based in Lake Forest, California.

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of CryoPort Inc (NASDAQ:CYRX) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $19.75.

  • [By Motley Fool Transcribers]

    CryoPort Inc (NASDAQ:CYRX)Q42018 Earnings Conference CallMarch 07, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on CryoPort (CYRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    CryoPort Inc (NASDAQ:CYRX) Director Richard J. Berman sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hot Stocks To Invest In Right Now: Arch Coal, Inc. (ARCH)

Arch Coal, Inc. is a coal producer. The Company is engaged in the production of thermal and metallurgical coal from surface and underground mines located throughout the United States, for sale to utility, industrial and steel producers both in the United States and around the world. The Company operates mining complexes in West Virginia, Kentucky, Maryland, Virginia, Illinois, Wyoming and Colorado. The Company’s segments include the Powder River Basin and Appalachia. The Powder River Basin segment includes operations in Wyoming. The Appalachia segment includes operations in West Virginia, Kentucky, Maryland and Virginia. The Company also sells coal from operations in Colorado and Illinois. Powder River Basin consists of Black Thunder and Coal Creek mines. The Company’s mines in Appalachia include Coal-Mac, Lone Mountain, Mountain Laurel, Beckley, Vindex, Sentinel and Leer. The Company operates, or contracts out the operation of approximately 10 active mines in the United States.
Advisors’ Opinion:

  • [By Max Byerly]

    Arch Coal Inc (NYSE:ARCH) declared a quarterly dividend on Thursday, February 14th, RTT News reports. Shareholders of record on Tuesday, March 5th will be paid a dividend of 0.45 per share by the energy company on Friday, March 15th. This represents a $1.80 dividend on an annualized basis and a yield of 2.01%. This is a positive change from Arch Coal’s previous quarterly dividend of $0.40.

  • [By Motley Fool Transcribers]

    Arch Coal, Inc. (NYSE:ARCH)Q42018 Earnings Conference CallFeb. 14, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Stocks To Invest In Right Now: Enersis S A(ENI)

Enersis S.A., an electric utility company, engages in the generation, transmission, and distribution of electricity in Chile, Argentina, Brazil, Colombia, and Peru. It owns and operates hydroelectric, thermal, and wind power plants. As of December 31, 2010, it had 14,833 megawatts of installed capacity with 195 power plants; and 13.3 million distribution customers covering approximately 50 million inhabitants. The company was formerly known as Compania Chilena Metropolitana de Distribucion Electrica S.A and changed its name to Enersis S.A. in August 1988. Enersis S.A. was founded in 1889 and is headquartered in Santiago, Chile. Enersis S.A. is a subsidiary of Endesa Latinoamerica S.A.

Advisors’ Opinion:

  • [By Shane Hupp]

    JPMorgan Chase & Co. set a €15.00 ($17.44) price objective on ENI (ETR:ENI) in a report published on Thursday morning. The firm currently has a sell rating on the stock.

  • [By Stephan Byrd]

    Morgan Stanley set a €16.70 ($19.42) price objective on ENI (ETR:ENI) in a report issued on Wednesday morning. The firm currently has a sell rating on the stock.

  • [By Shane Hupp]

    ENI (ETR:ENI) has been assigned a €18.50 ($21.76) price objective by equities researchers at Deutsche Bank in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 13.26% from the stock’s current price.

Hot Stocks To Invest In Right Now: ZIOPHARM Oncology Inc(ZIOP)

ZIOPHARM Oncology, Inc., incorporated on May 16, 2005, is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. The Company’s clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. Its Ad-RTS-IL-12 + veledimex uses gene delivery system to produce interleukin-12 (IL-12), a potent, naturally occurring anti-cancer protein. The Company’s initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

The Company in collaboration with Intrexon Corporation is focused on chimeric antigen receptor T cell (CAR+ T) products. The Company in collaboration with Intrexon plans to develop treatments for graft-versus-host disease (GvHD), a major complication of allogeneic hematopoietic stem-cell transplantation (HSCT), which impairs the quality of life and survival of many recipients. Allogeneic HSCT is used for the treatment of various diseases, including hematological malignancies, immunological deficiencies, as well as non-malignant conditions. Approximately 40 to 60% of HSCT recipients develop GvHD, either acute or chronic, when immune (graft) cells in a transplant patient recognize their engrafted host as foreign and attack the patient’s (host) cells. Immunosuppressive agents and systemic steroids routinely used to treat GvHD have limited efficacy and toxicity. Human studies have shown that administration of low-dose subcutaneous IL-2 in patients with steroid-refractory GvHD acts through Tregs to ameliorate its manifestations.

Ad-RTS-IL-12 + veledimex

The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. The Company is evaluating Ad-RTS-IL-12 + veledimex, in brain cancer and breast cancer. It h! as developed an adenoviral vector, Ad-RTS-IL-12, administered intratumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Gene expression and subsequent IL-12 protein production is tightly controlled by the activator ligand veledimex.

Ad-RTS-IL-12 + veledimex for malignant glioma

The Company has initiated the Phase I study for malignant glioma. The Food and Drug Administration (FDA) granted orphan drug designation of Ad-RTS-IL-12 + veledimex for the treatment of malignant glioma.

Ad-RTS-IL-12 + veledimex for metastatic breast cancer and melanoma

The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. The Company has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer.

The Company competes with Novartis/University of Pennsylvania, Bluebird bio/Celgene/Baylor College of Medicine, Kite Pharma/National Cancer Institute, Juno Therapeutics/Fred Hutchinson Cancer Research Center/Memorial Sloan-Kettering Cancer Center/Seattle Children’s Research Institute, Cellectis/Pfizer, Adaptimmune/GSK, Celgene, NantKwest, Amgen, AstraZeneca, Bristol-Myers, Incyte, Merck and Roche.

Advisors’ Opinion:

  • [By Logan Wallace]

    A number of hedge funds have recently bought and sold shares of ZIOP. MSD Partners L.P. increased its position in ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock valued at $20,544,000 after buying an additional 7,575,758 shares in the last quarter. FMR LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter valued at approximately $1,647,000. Ibex Investors LLC bought a new position in ZIOPHARM Oncology during the 4th quarter valued at approximately $755,000. Bank of America Corp DE increased its position in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares in the last quarter. Finally, Old West Investment Management LLC increased its position in ZIOPHARM Oncology by 784.7% during the 4th quarter. Old West Investment Management LLC now owns 223,319 shares of the biotechnology company’s stock valued at $417,000 after buying an additional 198,077 shares in the last quarter. 40.12% of the stock is owned by institutional investors.

    WARNING: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.9%” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at www.tickerreport.com/banking-finance/4199573/ziopharm-oncology-ziop-stock-price-up-8-9.html.

    ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

  • [By Motley Fool Transcribers]

    Ziopharm Oncology Inc (NASDAQ:ZIOP)Q42018 Earnings Conference CallMarch 05, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com